Table 5 Type of PARPi, therapy duration, reasons for treatment discontinuation, PFS1 and PFS2 among patients who received PARPi retreatment as maintenance therapy
ID | HRR status | Type of PARPi1 | PFS1 | Duration1 | Type of PARPi2 | PFS2 | Duration2 | reasons for treatment discontinuation | Duration1 > Duration2 |
|---|---|---|---|---|---|---|---|---|---|
1 | wt | Fluzoparib | 18.1 | 9.8 | Niraparib | 25.5 | 0.3 | ongoing | Yes |
2 | wt | Niraparib | 12.6 | 5.2 | Olaparib | 25.3 | 7.6 | PD | No |
3 | wt | Niraparib | 15.3 | 9.2 | Olaparib | 30.9 | 9.6 | PD | No |
4 | wt | Niraparib | 16.6 | 8.8 | Olaparib | 42.5 | 15.4 | ongoing | No |
5 | wt | Niraparib | 20.2 | 12.1 | Niraparib | 26.4 | 1.4 | PD | Yes |
6 | wt | Niraparib | 22.5 | 12.3 | Fluzoparib | 37.0 | 7.8 | PD | Yes |
7 | non BRCA1/2 HRR mt | Niraparib | 24.2 | 16.7 | Olaparib | 35.3 | 3.0 | PD | Yes |
8 | wt | Niraparib | 24.8 | 5.3 | Niraparib | 35.4 | 3.4 | PD | Yes |
9 | wt | Niraparib | 28.4 | 20.3 | Niraparib | 41.2 | 6.7 | ongoing | Yes |
10 | BRCA1 mt | Olaparib | 18.8 | 12.0 | Niraparib | 31.2 | 4.6 | PD | Yes |
11 | wt | Olaparib | 18.9 | 11.9 | Niraparib | 39.9 | 5.3 | PD | Yes |
12 | non BRCA1/2 HRR mt | Olaparib | 19.6 | 10.1 | Niraparib | 29.3 | 4.9 | PD | Yes |
13 | wt | Olaparib | 22.5 | 16.3 | Olaparib | 41.9 | 10.5 | PD | Yes |
14 | BRCA2 mt | Olaparib | 31.6 | 19.3 | Niraparib | 45.2 | 8.2 | PD | Yes |